Author: sbrands

Join the Biosimilars Movement | Nov 5 2021

We want to hear from you! This #GlobalBiosimilarsWeek, share your stories, information and educational resources, and initiatives so we can build a better world for biosimilars— together. Join the movement — be the voice of #biosimilars! https://bit.ly/GlobalBiosimilarsWeek #GlobalBiosimilarsWeek #GlobalBiosimilarsWeek is here, and education is a key step in understanding the importance of biosimilar adoption. This […]

Read More

Building a Better Future with Biosimilars | Nov 4 2021

Greater access to #biosimilar = more care for more patients. https://bit.ly/GlobalBiosimilarsWeek #GlobalBiosimilarsWeek #Biosimilars are the key to building a better future for patients around the globe. In order to provide more patients with more care, we need policies that support greater access to biosimilar medicines. #GlobalBiosimilarsWeek Join us in celebrating #GlobalBiosimilarsWeek! https://bit.ly/GlobalBiosimilarsWeek

Read More

Biosimilars and Patient Benefits | Nov 3 2021

With the lower treatment costs achieved thanks to #biosimilars, we can re-invest in other health care services – like childcare, eldercare, mental health services, research and more. #GlobalBiosimilarsWeek Biosimilars treatment costs for patients, government health programs and other payers, budget resources can be devoted to other health care initiatives. https://bit.ly/GlobalBiosimilarsWeek #GlobalBiosimilarsWeek By lowering treatment costs, […]

Read More

The Biosimilars Road Ahead | Nov 2 2021

The continued development of #biosimilars will promote health equity and access to care for millions of patients worldwide. Join the conversation with #GlobalBiosimilarsWeek. #Biosimilars: the future of sustainable healthcare. #GlobalBiosimilarsWeek This #GlobalBiosimilarsWeek, join us in looking at the road ahead for the #biosimilars industry. As more biosimilars are developed and approved, they will promote health […]

Read More

Today’s Biosimilars Landscape | Nov 1 2021

Q: What are #biosimilars? A: Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic. Biosimilars provide an opportunity to create competition in the market and expand patient access to critical medicines. #GlobalBiosimilarsWeek https://bit.ly/GlobalBiosimilarsWeek Safe and effective #biosimilars have been available for over 15 years. As more biosimilars come to market, […]

Read More

Extrapolation of Indications

From the desk of Henry Leng Extrapolation, when used in the context of biosimilars, means their registration for all the indications of the reference product without the need to conduct clinical trials to support each of those indications.  The assumption that is made by most regulatory specialists, whether from industry or the regulatory authority, is […]

Read More

Interchangeability of Biosimilars

From the Desk of Henry Leng The availability of biosimilars provides an affordable treatment option for many patients suffering from debilitating chronic diseases (rheumatoid arthritis, psoriasis, several cancers, etc.) who previously had no access to biologics because of the high cost of the patent-protected innovator medicines.  However, the full potential of biosimilars in South Africa will […]

Read More

Evaluation & Registration Pathway for Biosimilars

From the desk of Henry Leng The guideline for the registration of biosimilars in South Africa, Biosimilar medicines: quality, non-clinical and clinical requirements, was first published in 2012; yet it took six years for the first biosimilar to be registered (Filgrastim Teva in 2018).  Biosimilar registration applications were already received in since 2006 by the Medicines Control […]

Read More

Science-driven Evolution for Sustainable Access to Biologics

The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, welcomes the UK MHRA publication of its updated guidance on the licensing of biosimilar products (10 May 2021). This publication marks a positive milestone in the evolution of evidence requirements for biosimilar approval through the removal of the […]

Read More